Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki Sato sold 22,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $5.84, for a total value of $128,480.00. Following the sale, the director directly owned 1,232,391 shares of the company’s stock, valued at $7,197,163.44. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vir Biotechnology Price Performance

VIR opened at $5.73 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The business has a 50-day moving average of $4.99 and a 200-day moving average of $5.34. The company has a market capitalization of $796.01 million, a PE ratio of -1.43 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.38 million. During the same period last year, the business earned ($1.02) earnings per share. The firm’s revenue for the quarter was down 60.5% on a year-over-year basis. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

VIR has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Evercore ISI initiated coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price objective on the stock. Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their price objective for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Raymond James Financial initiated coverage on Vir Biotechnology in a research note on Friday, July 11th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vir Biotechnology in a research note on Saturday, September 27th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.30.

Institutional Trading of Vir Biotechnology

Institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Vir Biotechnology during the 1st quarter worth approximately $78,000. Cinctive Capital Management LP acquired a new stake in Vir Biotechnology in the 1st quarter valued at $547,000. GAMMA Investing LLC boosted its stake in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after buying an additional 5,972 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after buying an additional 225,544 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Vir Biotechnology in the first quarter worth $2,324,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).